Abstract. The pineal gland is a complex neuroendocrine organ which is under photoneuroendocrine control. Previous studies in animals and humans have suggested reciprocal variations in pineal melatonin biosynthesis and adrenal glucocorticoid output; it remains unclear, however, whether a causal relationship exists between these two systems. To address this question, we examined the overnight secretory activity of the hypothalamic-pituitary-adrenal (HPA) axis in conjunction with acute pharmacological suppression of pineal melatonin biosynthesis in 11 healthy volunteers. Results of the current study are consistent with the hypothesis that melatonin does not function as a tonic inhibitor of the HPA axis on an acute basis.
. Studies in humans have suggested the possibility of an inverse association between pineal and adrenal activity in affective illness (Beck-Friis et al., 1985; Frazer et al., 1986) ; it is unclear, however, whether thereisacausalrelationship in either direction.
To examine further the possible association between activity of the pineal gland and the HPA axis in normal individuals, weexamined the overnight secretory activity ofthe HPA axis in conjunction with acute pharmacological suppression of nocturnal melatonin release. Blockade of nocturnal melatonin release was obtained with the /3-adrenergic antagonists propranolol and atenolol. We chose to compare the effects of these two agents since propranolol is a nonselective, lipophilic P-adrenergic receptor antagonist and therefore blocks both PI-and &-adrenergic receptors centrally and peripherally.
Atenolol, on the other hand, is a selective fi,-adrenergic receptor, nonlipophilic P-blocker. Therefore, it may be theoretically more selective in blocking the peripherally located P,-adrenergic receptors on the pinealocytes while having little penetration into the central nervous system. Parenthetically, catecholaminergicstimulation of pituitary release of adrenocorticotropic hormone (ACTH) appears to occur via &-adrenergic receptors, suggesting little effect of atenolol on this mechanism (Mezey et al., 1983) .
Methods
Subjects. Eleven subjects (7 males, 4 females, age range 20-33) were recruited. All subjects were interviewed before the study and underwent a complete physical examination to rule out significant medical or psychiatric illness. All subjects refrained from using medications, alcohol, and caffeine and had been on a regular schedule of 8-9 hours of sleep (10:30-l 1:30 p.m. until 6:30-7:30 a.m.) for 2 weeks before each study night.
Procedure. Three separate studies were performed, at least 2 weeks apart from one another. All subjects underwent studies in the same order. For study 1, subjects were instructed to collect all urinevoidedafter6p.m.,up toandincludingafinalvoidat 1Oa.m. thefollowingmorning. Study2 involved a urine collection as above. In addition, at 6p.m. duringstudy 2,eachsubject wasgivena dose of 60 mg of propranolol. Pulse and blood pressure were then monitored for the next 2 hours. At lo:30 p.m., an additional dose of 40 mg of propranolol was given. Pulse and blood pressure were again monitored for an hour. Study 3 was similar in format to study 2 with the substitution of atenolol for propranolol in dosages of 50 mg and 25 mg at 6 p.m. and lo:30 p.m., respectively. No patients reported adverse effects from the dosages of @blockers administered. Urine was aliquoted within 2 hours of final collection and frozen at -70 "C until assayed. Urinary free cortisol was measured by competitive protein binding assay as previously described (Contreras et al., 1986) . Intra-assay and interassay variabilities were 7.6% and 12.5%, respectively. The principal urinary metabolite of melatonin, 6-hydroxymelatonin, was assayed by gas chromatography/mass spectrometry, as previously described (Tetsuo et al., 1981) . Intra-assay and interassay variabilities were < 6%.
Results

Acute administration
of either 100 mg of propranolol or 75 mgof atenolol resulted in an almost complete pharmacological ablation of the nocturnal surge of 6-hydroxymelatonin excretion (baselinemean+SD= 13721+4945ng/TVvs. 1413 f 1138 ng/TV on propranolol, p < 0.006, and 2961 + 1850 ng/TV on atenolol,p < 0.006) (Fig. la) . However, no significant differences were seen in overnight urinary free cortisol excretion between study 1 and either of the two subsequent studies (baseline mean + SD = 31*41.~g/TVvs, 35 f 7 pg/TV on propranololand30*3pg/TVonatenolol)( Fig.  16 ). Significant reductions in pulse and blood pressure were noted during the treatment nights (Table 1) . No discomfort was reported by any subject. 
Discussion
In the present study, we have shown that acute pharmacological blockade of melatonin biosynthesis was not associated with a concomitant rise of overnight cortisolsecretion. In addition,
we have replicated previous findings that both propranolol and the nonlipophilic, P,-selective adrenergic receptor antagonist atenolol produce a dramatic reduction of the nocturnal melatoninsurge (Cowenet al., 1983; Arendt et al., 1985) . The absence of an inverse association between melatonin and cortisol after reduction in melatonin secretion is consistent with the hypothesis that melatonin does not function as a tonic inhibitor of the HPA axis on an acute basis.
A variety of studies in animals have suggested an inhibitory effect of melatonin on cortisol secretion (Wurtman et al., 1959 (Wurtman et al., , 1961 Vaughan et al., 1972) . Although the mechanism of melatonin-induced decrease of adrenal gland weight was not definitively elucidated, data indicating a concomitant decrease in plasma ACTH secretion strongly suggest a hypothalamic or pituitary mechanism may be involved (Kinson et al., 1968) . Investigation of the role of glucocorticoids on pineal biosynthesis has been less extensively reported. The definitive presence of glucocorticoid receptors in pinealocytes has not been noted, although JH-dexamethasone concentrates in the pinealgland (Warembourg, 1975) . In cell culture, glucocorticoids have been reported to inhibit the melatonin increase seen with noradrenergic stimulation (Fevre-Montagne and AbouSamra, 1983). Lipocortin, the tissue mediator of glucocorticoid effects on prostaglandin biosynthesis, is widely distributed throughout the body, including the brain (Wallner et al., 1986) . In this regard, it is interesting that in wholeorganpinealcultures, glucocorticoids appear to inhibit the noradrenergically stimulated release of arachidonic acid, possibly through lipocortindependent inhibition of phospholipase A2 activity (Demitrack et al., unpublished observations). A possible developmental role for glucocorticoids in the modulation of pineal biosynthetic activity has beensuggested by the work of Yuwiler (1985) , who demonstrated that neonatal exposure to glucocorticoids in the rat produces a reduction of noradrenergically stimulated SNAT activity in the adult rat.
Clinical studies in humans suggest a complex relationship between the pineal and adrenal glands. In studies of affectively ill individuals, a number of investigators have suggested an inverse relationship between melatonin and cortisol, with a blunting ofthe normal nocturnal melatonin rise (Beck-Friis et al., 1983; Frazer et al., 1986) , although this finding has not been universally replicated (Thompson et al., 1988) . In some instances, this abnormality appears to persist into the euthymic state (Beck-Friis et al., 1983), a finding which may be of interest in light of the work of Yuwiler noted above (i.e., peristent reduction of nocturnal melatonin may occur as a consequence of repeated activation of the HPA axis in early life. Interestingly, acute administration of glucocorticoids to normal subjects has not been reliably shown to produce a reduction in melatonin secretion at night (Beck-Friis et al., 1983; Demisch et al., 1987 The findings of this pilot study demonstrate that acute reductions inmelatonin levels induced by P-blockers are not associated with concomitant increases in cortisol secretion. This is consistent with the hypothesis that in the normal individual melatonin does not serve as a tonic inhibitor of cortisol release. It should be noted that the dose of propranolol chosen in this study resulted in a mean reduction of melatonin from baseline of 90% compared with a mean reduction of 80% with the administration of atenolol. While these results are comparable, the possibility cannot be excluded that a higher dose of atenolol would have yielded positive results that were otherwise obscured by small but significant levels of circulating melatonin. As a corollary finding, it is also of interest that acute challenge with propranolol did not appear to affect cortisol secretion.
As noted previously, catecholamine modulation of HPA axis function may occur via direct pituitary stimulation of &-adrenergic receptors. The results obtained in the present study would suggest that catecholamines do not tonically stimulate HPA axis activity on an acute basis.
In sum, it remains to be determined whether, in the normal individual, more chronic alterations of adrenal activity or biosynthesis of melatonin may be associated with one another. Further, associated disturbances of these two systems in pathological states such as depression and anorexia nervosa may differ significantly from the normal individual and should be interpreted in light of known alterations in other neuroendocrine axes. 
